SOPHiA GENETICS (NASDAQ:SOPH) Insider Sells $21,417.05 in Stock

SOPHiA GENETICS SA (NASDAQ:SOPH) insider Manuela Valente sold 4,241 shares of the stock in a transaction on Monday, July 6th. The stock was sold at an average price of $5.05, for a total transaction of $21,417.05. Following the completion of the transaction, the insider directly owned 210,450 shares in the company, valued at $1,062,772.50. The trade was a 1.98% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Manuela Valente also recently made the following trade(s):

• On Monday, April 20th, Manuela Valente sold 380 shares of SOPHiA GENETICS stock. The stock was sold at an average price of $5.20, for a total value of $1,976.00.
• On Wednesday, April 8th, Manuela Valente sold 3,824 shares of SOPHiA GENETICS stock. The stock was sold at an average price of $4.85, for a total value of $18,546.40.

SOPHiA GENETICS Price Performance

Shares of SOPHiA GENETICS stock opened at $5.82 on Friday. SOPHiA GENETICS SA has a 52-week low of $2.92 and a 52-week high of $6.30. The stock has a market capitalization of $488.24 million, a price-to-earnings ratio of -11.19 and a beta of 0.96. The company has a fifty day moving average of $5.16 and a 200-day moving average of $4.98. The company has a debt-to-equity ratio of 1.05, a quick ratio of 1.90 and a current ratio of 2.06.

SOPHiA GENETICS (NASDAQ:SOPH) last posted its quarterly earnings results on Tuesday, May 5th. The company reported ($0.27) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.23) by ($0.04). SOPHiA GENETICS had a negative return on equity of 62.74% and a negative net margin of 44.48%.The company had revenue of $21.69 million for the quarter, compared to the consensus estimate of $20.40 million.

Analyst Upgrades and Downgrades

A number of research firms recently issued reports on SOPH. Weiss Ratings reissued a “sell (d-)” rating on shares of SOPHiA GENETICS in a research note on Tuesday, April 21st. BTIG Research reiterated a “buy” rating and set a $8.00 target price on shares of SOPHiA GENETICS in a report on Monday, June 15th. Two analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company. According to MarketBeat, the stock currently has an average rating of “Hold” and a consensus price target of $7.50.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently made changes to their positions in the company. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC lifted its position in SOPHiA GENETICS by 246.9% in the 1st quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 7,632,871 shares of the company’s stock valued at $25,341,000 after acquiring an additional 5,432,871 shares in the last quarter. Federated Hermes Inc. increased its holdings in shares of SOPHiA GENETICS by 16.4% in the 2nd quarter. Federated Hermes Inc. now owns 220,000 shares of the company’s stock worth $682,000 after purchasing an additional 31,000 shares in the last quarter. Akre Capital Management LLC increased its holdings in shares of SOPHiA GENETICS by 66.2% in the 2nd quarter. Akre Capital Management LLC now owns 3,719,140 shares of the company’s stock worth $11,529,000 after purchasing an additional 1,481,636 shares in the last quarter. Dimensional Fund Advisors LP raised its stake in shares of SOPHiA GENETICS by 24.7% in the third quarter. Dimensional Fund Advisors LP now owns 31,332 shares of the company’s stock worth $148,000 after purchasing an additional 6,205 shares during the last quarter. Finally, Squarepoint Ops LLC purchased a new position in shares of SOPHiA GENETICS in the third quarter worth $49,000. Institutional investors own 31.59% of the company’s stock.

SOPHiA GENETICS Company Profile

SOPHiA GENETICS SA is a data-driven medicine company founded in 2011 and headquartered in La Tène, Switzerland. The firm develops and operates a cloud-native software platform designed to standardize and analyze complex genomic and radiomic data. Its core offering, the SOPHiA DDM™ platform, leverages artificial intelligence and machine learning algorithms to help healthcare institutions, laboratories and biopharmaceutical partners derive actionable insights from next-generation sequencing and medical imaging datasets.

The SOPHiA DDM™ platform supports a range of clinical applications, including oncology, hereditary diseases and rare genetic disorders.